HIV testing and unreported HIV positivity among injecting drug users in London.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

HIV testing and unreported HIV positivity among injecting drug users in London.

AIDS. 1993 Aug;7(8):1105-11. Unique Identifier : AIDSLINE MED/94000542
Donoghoe MC; Rhodes TJ; Hunter GM; Stimson GV; Centre for Research on Drugs and Health Behaviour, Charing Cross; and Westminster Medical School, University of London, UK.

Abstract: OBJECTIVE: To assess the importance of community-recruited drug injectors with no treatment experience and no previous testing history when estimating HIV prevalence among drug injectors. DESIGN: HIV testing behaviour and prevalence were measured in a serial point prevalence study of drug injectors recruited in community-based non-treatment and treatment settings. METHODS: Pearson's chi 2 and Fisher's exact tests were used to measure differences between treatment groups and non-treatment groups in demographic characteristics, including age and length of injecting career, recent drug use, recent syringe sharing, uptake of previous HIV testing, confirmed HIV-antibody status by saliva and self-reported HIV status. RESULTS: Rates of HIV-antibody testing were significantly lower in community-recruited drug injectors with no experience of treatment than those previously or currently in treatment. Confirmed HIV prevalence by saliva was highest in drug injectors with no experience of treatment. HIV-antibody-positive drug injectors with no treatment experience were less likely to be aware of their antibody status than injectors who were, or who had been, in treatment. CONCLUSIONS: Previous studies of HIV prevalence among drug injectors may be biased by drawing on samples primarily from treatment settings. Drug injectors with no treatment experience and no previous history of HIV testing should be included in HIV prevalence studies. Regular and repeat HIV testing in low-threshold community-based programmes should be considered a necessary part of interventions which seek to provide better access to treatment and other HIV prevention services.

Keywords: Adult Demography Female Human HIV Infections/COMPLICATIONS/DIAGNOSIS/*EPIDEMIOLOGY *HIV Seroprevalence London/EPIDEMIOLOGY Male Risk Factors Saliva/IMMUNOLOGY Substance Abuse, Intravenous/*COMPLICATIONS Support, Non-U.S. Gov't JOURNAL ARTICLE
940130
M9410785

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .